LivaNova PLC (LIVN) shares surged 10.64% in pre-market trading on Wednesday following the release of better-than-expected first-quarter 2025 results, raised full-year guidance, and positive clinical data for its sleep apnea treatment.

The medical technology company reported Q1 revenue of $316.9 million, surpassing the IBES estimate of $302.3 million. Adjusted earnings per share came in at $0.88, significantly beating the expected $0.76. LivaNova's strong performance was driven by high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion.

In light of the robust results, LivaNova raised its full-year 2025 revenue growth guidance to 6.0% to 7.0% on a constant-currency basis, up from the previous range of 5.0% to 6.0%. The company also announced positive 12-month data from its OSPREY clinical study for moderate to severe obstructive sleep apnea, demonstrating strong response and durability of therapy. The study showed an overall responder rate of 65% and a 68% reduction in both the median Apnea-Hypopnea Index and Oxygen Desaturation Index, potentially opening up new growth opportunities for LivaNova in the sleep apnea market.